Glenmark Pharma gets USFDA nod to market drug for relapsing multiple sclerosis

Drug major Glenmark Pharma said it has received final approval from the US health regulator for Dimethyl Fumarate delayed-release capsules, used for the treatment of relapsing forms of multiple sclerosis in adults.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news